All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F16%3AN0000190" target="_blank" >RIV/00064173:_____/16:N0000190 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.1097/IAE.0000000000001004" target="_blank" >http://dx.doi.org/10.1097/IAE.0000000000001004</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1097/IAE.0000000000001004" target="_blank" >10.1097/IAE.0000000000001004</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study

  • Original language description

    Purpose: To evaluate the occurrence, management, and clinical significance of increases in intraocular pressure (IOP) in patients with diabetic macular edema treated with dexamethasone intravitreal implant (DEX implant). Methods: Randomized, multicenter, 3-year, Phase III study. Patients (N = 1,048) with diabetic macular edema were randomized to DEX implant 0.7-mg, DEX implant 0.35-mg, or sham procedure with retreatment allowed at >= 6-month intervals (seven injections maximum). Results: In the DEX implant 0.7-mg, DEX implant 0.35-mg, and sham groups, respectively, >= 10-mmHg IOP increases from baseline occurred in 27.7%, 24.8%, and 3.7% of patients, and their frequency did not increase with repeat injections. IOP-lowering medication was used by 41.5%, 37.6%, and 9.1% of patients. Only one patient (0.3%) in each DEX implant group had filtering surgery to manage a steroid-induced IOP increase. Among DEX implant 0.7-mg-treated patients with and without a >= 10-mmHg IOP increase, 21.9% (21 of 96) and 22.4% (57 of 255), respectively, achieved >= 15-letter best-corrected visual acuity gain at the end of the study, and mean average change in central retinal thickness from baseline was -127 mm and -106 mm, respectively. Conclusion: DEX implant demonstrated clear benefit of treatment despite increases in IOP. Sequential implants had no cumulative effect on IOP.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FF - ENT (ie. ear, nose, throat), ophthalmology, dentistry

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Retina

  • ISSN

    0275-004X

  • e-ISSN

  • Volume of the periodical

    36

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    10

  • Pages from-to

    1143-1152

  • UT code for WoS article

    000377139100028

  • EID of the result in the Scopus database

    2-s2.0-84957927695